Outcomes of Percutaneous Coronary Intervention in Hospitalized Patients with Acute Coronary Syndrome and Heart Failure: Insights from the CCC-ACS Registry Observational Study - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Outcomes of Percutaneous Coronary Intervention in Hospitalized Patients with Acute Coronary Syndrome and Heart Failure: Insights from the CCC-ACS Registry Observational Study

  • By

  • Chu Fan

  • Hangyu Yan

  • Kehang Lei

  • Dan Li

  • Shutong Dong

  • Yue Zhang

  • Cecily Patricia Callister

  • Yutong Cheng

  • Zhao Li

  • Zhizhong Li

  • Haiyan Qian

  • Ji Huang

  • December 30, 2025

Share

Clinical Scorecard: Outcomes of Percutaneous Coronary Intervention in Hospitalized Patients with Acute Coronary Syndrome and Heart Failure: Insights from the CCC-ACS Registry Observational Study

At a Glance

CategoryDetail
ConditionAcute Coronary Syndrome with Heart Failure
Key MechanismsEarly revascularization improves myocardial blood supply, reverses myocardial stunning, and enhances contractile function.
Target PopulationPatients with Acute Coronary Syndrome and Heart Failure, particularly those with Killip class ≥ II.
Care SettingTertiary and secondary hospitals in China.

Key Highlights

  • PCI is the primary therapeutic strategy for coronary revascularization in ACS.
  • Patients with ACS and HF are classified as extremely high-risk.
  • The CCC-ACS registry included 4,694 ACS patients with HF for analysis.

Guideline-Based Recommendations

Diagnosis

  • ACS defined per Chinese Society of Cardiology guidelines.
  • Heart failure defined per European Society of Cardiology guidelines.

Management

  • Primary PCI recommended for STEMI within 6 hours of symptom onset.
  • NSTE-ACS patients assessed based on risk stratification.

Monitoring & Follow-up

  • LVEF measured by echocardiography within 24 hours of admission.

Risks

  • Patients with ACS-HF have complex conditions and require urgent evaluation.

Patient & Prescribing Data

Patients with ACS and HF admitted within 24 hours after first medical contact.

Optimal medical therapy includes β-blockers, ACEI/ARB, and ARAs for patients not undergoing PCI.

Clinical Best Practices

  • Utilize dual antiplatelet therapy (DAPT) during hospitalization.
  • Monitor for major adverse cardiovascular events (MACCE) during hospitalization.

Related Resources & Content

Original Source(s)

Related Content